Identification technologies to support Alzheimer contexts

Alzheimer's disease makes great demands on care by assistants, due to the fact that they cannot distract their attention from patients while they are at the same time managing records. For that reason, technologies to complement this process need to be adapted. In this work we present a proposal to adapt identification technologies: Radiofrequency Identification (RFID) and Near Field Communications (NFC), focusing especially on the last one. We fuse both technologies and apply them to an Alzheimer's day center. Patients are tagged with two kinds of labels: 13.56Mhz.Mifare for NFC and UHF for RFID. With the first one we tag the context, which means patients, devices (displays, exercise books, etc) and places. With a simple interaction, which involves touching tags with mobile phones, it is possible to manage the information easily. Moreover, with RFID, we localize each patient by the simple act of their passing by an antenna placed in the doors.

Peripheral brain-derived neurotrophic factor levels in alzheimer's disease and mild cognitive impairment: A comprehensive systematic review and meta-analysis

Alzheimer's disease (AD) is becoming a growing global problem, and there is an urgent need to identify reliable blood biomarkers of the risk and progression of this condition. A potential candidate is the brain-derived neurotrophic factor (BDNF), which modulates major trophic effects in the brain. However, findings are apparently inconsistent regarding peripheral blood BDNF levels in AD patients vs. healthy people. We thus performed a systematic review and meta-analysis of the studies that have examined peripheral BDNF levels in patients with AD or mild cognitive impairment (MCI) and healthy controls. We searched articles through PubMed, EMBASE, and hand searching. Over a total pool of 2061 potential articles, 26 met all inclusion criteria (including a total of 1584 AD patients, 556 MCI patients, and 1294 controls). A meta-analysis of BDNF levels between early AD and controls showed statistically significantly higher levels (SMD [95 % CI]: 0.72 [0.31, 1.13]) with no heterogeneity. AD patients with a low (<20) mini-mental state examination (MMSE) score had lower peripheral BDNF levels compared with controls (SMD [95 % CI]: -0.33 [-0.60, -0.05]). However, we found no statistically significant difference in blood (serum/plasma) BDNF levels between all AD patients and controls (standard mean difference, SMD [95 % CI]: -0.16 [-0.4, 0.07]), and there was heterogeneity among studies (P < 0.0001, I 2 = 85.8 %). There were no differences in blood BDNF levels among AD or MCI patients vs. controls by subgroup analyses according to age, sex, and drug use. In conclusion, this meta-analysis shows that peripheral blood BDNF levels seem to be increased in early AD and decreased in AD patients with low MMSE scores respectively compared with their age- and sex-matched healthy referents. At present, however, this could not be concluded from individual studies.

“Ana”: Apología de la enfermedad como estilo de vida

SIN FINANCIACIÓN